FDA Proposed Rule Will Require MedDRA for Postmarketing AE Reporting
Executive Summary
FDA's Suspected Adverse Drug Reaction proposed rule will seek to require the use of MedDRA terminology in submissions of postmarketing adverse event reports, the agency told a Drug Information Association workshop on MedDRA implementation Oct. 30 in Washington, D.C.
You may also be interested in...
Foreign Safety Data Sought By FDA Under Proposed Rule On Periodic Updates
FDA's safety reporting rule would require drug and biologic sponsors to review any safety information acquired from a foreign regulatory authority to determine whether it should be reported to the agency
Foreign Safety Data Sought By FDA Under Proposed Rule On Periodic Updates
FDA's safety reporting rule would require drug and biologic sponsors to review any safety information acquired from a foreign regulatory authority to determine whether it should be reported to the agency
FDA Adverse Event Rating Scale Could Follow NCI Model, Consultant Says
The National Cancer Institute Common Toxicity Criteria could be a model for a standardized adverse event severity scale, International Pharmaceutical Consultants President Herbert Swarz, MD, suggested during a May 22 FDA hearing on risk management